Combination Immunotherapeutic Strategies For Haematological Cancers
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
Patients with lymphoma cancers initially respond well to treatment, but later relapse with disease. The immune system can be effective at controlling cancer. A potential treatment option is to boost the natural immune response against cancer. This study investigates a novel vaccine that activates a certain immune cell, NKT cells, to fight lymphomas by delivering an NKT cell-activating molecule. Outcomes will allow assessment of combining an NKT-based vaccine with established treatments for lymph ....Patients with lymphoma cancers initially respond well to treatment, but later relapse with disease. The immune system can be effective at controlling cancer. A potential treatment option is to boost the natural immune response against cancer. This study investigates a novel vaccine that activates a certain immune cell, NKT cells, to fight lymphomas by delivering an NKT cell-activating molecule. Outcomes will allow assessment of combining an NKT-based vaccine with established treatments for lymphoma.Read moreRead less
Human Dendritic Cell Subsets And Their Application For Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$443,946.00
Summary
Immunotherapy is a promising non-toxic strategy for the treatment of many cancers, viruses and other diseases. It works by teaching the patient's own immune system to recognize and destroy the cancer. Specialized blood cells called dendritic cells are essential to this process but they are poorly understood in humans. I aim to investigate the function these cells and use this information to develop new treatments for cancer and viruses.
Advanced Population-based Methods To Evaluate And Inform Immunisation Policy And Practice
Funder
National Health and Medical Research Council
Funding Amount
$425,048.00
Summary
Despite the overall success of immunisation programs, preventable infections continue to occur, with Aboriginal children suffering the most. I will study the health and vaccination records for 1.95 million children (98,000 Aboriginal) in New South Wales and Western Australia to see who is most at risk of vaccine preventable infections and why. The findings will aid development of strategies to target high-risk children and to optimise the benefits obtained from Australia’s immunisation program.
Evaluation Of Future Cervical Cancer Prevention Strategies In Australia
Funder
National Health and Medical Research Council
Funding Amount
$401,361.00
Summary
The overall aim of the project is to use simulation modelling to perform a detailed epidemiologic and economic evaluation of the role of primary HPV DNA testing in Australia in the context of HPV vaccination. The project involves a collaboration with investigators at the National Cancer Institute USA, to analyse data from large studies conducted around the world and to build an accurate simulation of HPV infection and the development of cervical cancer.
Protecting Australia From Future Swine Flu Pandemics-Functional And Structural Studies Of The H1N1 Swine Influenza A Surface Glycoprotein Hemagglutinin
Funder
National Health and Medical Research Council
Funding Amount
$401,361.00
Summary
The severity of the present and future pandemic strains of the swine flu will depend on the ability to contain and combat infection via pre-emptive development of appropriate vaccines and drugs. To this end, my study of the surface glycoprotein hemagglutinin, will help predict and prevent future swine influenza pandemics by identifying potentially pandemic strains to be targeted for early vaccine development.
Dendritic Cells In Innate Immunity And Their Potential Clinical Manipulation
Funder
National Health and Medical Research Council
Funding Amount
$443,946.00
Summary
Dendritic cells (DC) are rare cells that are crucial in response to infection and surveillance of damaged tissues. We aim to understand the tools that are expressed by DC that allow them to sense pathogens and the functions of different DC types once a pathogen has been detected. The ultimate aim is to be able to understand and harness the functions of different DC so that we may directly target them upon demand to aid in the course of infection or potentially as tumour therapy.
HIV is one of the highest public health priorities of our time. Traditional vaccines have been unsuccessful highlighting the need for alternative approaches to HIV vaccine design. We propose to modify a novel technology developed initially for targeted drug delivery, termed “capsules”, for the purpose of inducing an immune response. This is a generic technology with applications for other infectious diseases and cancer and brings together disparate disciplines of nanochemistry and immunology.
VACCINE SAFETY RESEARCH In Understudied And At Risk Groups: Critical Knowledge To Inform Practice And Policy.
Funder
National Health and Medical Research Council
Funding Amount
$290,041.00
Summary
Vaccines are typically given to healthy individuals and therefore safety issues loom high on the list of public concerns. Vaccine hesitancy due to safety concerns is an issue of increasing global interest and threatens to lower vaccine uptake. My research aims to understand why some people experience adverse reactions to vaccines, do genetic markers exist?, what are the long term outcomes of a vaccine reaction and how best to communicate vaccine risk/safety to the Australian community.
Pneumococcal disease is one of the biggest killers of children under 5 years of age worldwide, mostly in developing countries. Pneumococcal conjugate vaccines are highly effective at reducing pneumococcal disease however the duration of protection and the immune factors involved is unknown, particularly when fewer than the recommended number of doses are used. My fellowship aims to examine the key immune factors that provide long-term protection following pneumococcal vaccination.